Ah, the paradox of protocol design - on one hand you have to build a scientifically rich program that produces all the data you need; on the other hand, if you throw too much into it, patients can be overwhelmed and even drop out, sites can struggle, and yoru own teams might get bottlenecked by unanticipated new challenges resulting from protocol complexity. We know that clinical trial protocols must answer increasingly sophisticated scientific questions, often across narrowly defined patient populations and complex treatment pathways. It's easy to justify - scientifically - adding endpoints, assessments, eligibility requirements, and data collection activities.
But, the flipside has real consequences for study success. A longer visit schedule can increase patient burden. Additional procedures can narrow the number of sites capable of conducting the study. More restrictive eligibility criteria can increase screen failures and extend enrollment. Greater data collection can create additional work for coordinators, monitors, and data management teams.
Protocol complexity is therefore more than just a concern about whether a study looks difficult to execute. It is a measurable risk that can affect enrollment, retention, site performance, timelines, and cost.
Complexity Accumulates Across the Protocol
No single requirement necessarily makes a clinical trial unmanageable. Problems often emerge from the cumulative effect of many reasonable decisions.
A study may require frequent visits, lengthy assessments, multiple patient-reported outcomes, specialized imaging, laboratory testing, and tightly controlled treatment windows. Each element may support an important objective, but together they create a demanding experience for participants and sites.
Traditional protocol reviews do not always reveal this cumulative burden. Different functions may evaluate separate components of the study, with medical teams reviewing endpoints, data teams examining collection requirements, and operational teams assessing execution. Without a shared view of the complete protocol, complexity can grow across functions without anyone fully seeing its combined impact.
Measuring complexity creates a common basis for evaluating these decisions before the protocol is finalized.
Patient Burden Can Be Quantified
Patient burden is often discussed as a general principle, but many of its components can be evaluated directly. Teams can examine the number and duration of visits, travel expectations, blood draw volumes, invasive procedures, digital tasks, diary requirements, and time away from work or family responsibilities.
These measures can then be assessed against the characteristics of the intended patient population. A visit schedule that appears manageable for one population may be unrealistic for people living with mobility limitations, fatigue, cognitive impairment, or advanced disease. The same requirements may also affect patients differently depending on geography, transportation access, employment, and caregiver availability.
This analysis helps teams identify which protocol requirements are most likely to discourage participation or contribute to dropout. It can also reveal where flexible scheduling, remote options, transportation support, or fewer assessments could meaningfully improve the patient experience without compromising scientific objectives.
Site Burden Shapes Feasibility
Protocol complexity also influences how many sites can realistically conduct a study. Specialized procedures, extensive training, demanding data entry, complicated technology, and narrow scheduling windows can quickly reduce the pool of qualified and willing research centers.
Site burden can be measured through expected staff time, required roles, procedure volume, technology demands, pharmacy responsibilities, monitoring activity, and the time needed to complete each visit. These factors affect both operational capacity and financial sustainability.
A site may have access to eligible patients and a strong performance history but still decline a study because its staffing requirements or workflow demands are impractical. Even sites that accept the study may struggle to maintain enrollment and data quality if the protocol places excessive pressure on coordinators and investigators.
Evaluating site burden during protocol development provides a more realistic picture of feasibility than patient and site counts alone.
Complexity Has Downstream Financial Consequences
The effects of protocol complexity continue throughout the study lifecycle. Difficult eligibility criteria may produce higher screen failure rates. Overly demanding visits can slow enrollment and contribute to participant withdrawal. Specialized requirements can increase vendor costs, site payments, monitoring needs, and training demands.
Complex protocols may also require amendments when early assumptions prove unrealistic. Those amendments can trigger additional reviews, system updates, document revisions, translations, site retraining, and participant communication. Even a relatively small change can create significant work across countries, sites, technologies, and functional teams.
Quantifying complexity allows organizations to treat these outcomes as foreseeable risks rather than isolated execution problems. It also helps teams compare the operational cost of a requirement with the scientific value it is expected to provide.
Data Can Improve Protocol Decisions
Historical trial data provides an important foundation for complexity analysis. Organizations can examine how previous design choices affected enrollment speed, screen failures, site activation, protocol deviations, amendments, retention, and cost.
Real-world data can add further context by testing assumptions about the available patient population and current standards of care. Patient and site feedback can reveal practical burdens that are difficult to identify through structured data alone.
Artificial intelligence can help teams organize these inputs, identify patterns, compare protocols, and model alternative design scenarios. Its greatest value lies in supporting more informed decisions while changes are still possible. Human experts must still determine whether a requirement is scientifically necessary, operationally realistic, and appropriate for the population being studied.
Making Complexity Visible Earlier
Protocol development will always involve tradeoffs. Reducing complexity does not mean removing every demanding procedure or simplifying a study at the expense of scientific rigor. Some requirements are essential to answering the research question and protecting participants.
The objective is to make those tradeoffs visible. When teams can quantify patient burden, site workload, eligibility constraints, and downstream cost, they can distinguish necessary complexity from requirements that add limited value.
That visibility supports stronger cross-functional discussions and gives decision-makers a clearer understanding of how protocol choices may affect execution. It also creates opportunities to redesign difficult elements before they become embedded in study systems, contracts, training, and site workflows.
Protocol complexity cannot always be eliminated, but it can be measured, evaluated, and managed. Organizations that develop this discipline will be better prepared to create studies that preserve scientific quality while remaining feasible for the patients and sites responsible for bringing them to life.
Continue the Conversation at SCOPE Summit Europe
Protocol optimization, patient and site burden, and data-informed trial design will be important areas of discussion at SCOPE Summit Europe. Leaders from across the clinical research ecosystem will explore how sponsors can identify operational risks earlier and design studies that are both scientifically rigorous and practical to execute.
Learn more and register here.